Cover Image
市場調查報告書

睪酮(睪丸激素)替代療法 (TRT)的全球市場:2016年∼2020年

Global Testosterone Replacement Therapy Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 365949
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
睪酮(睪丸激素)替代療法 (TRT)的全球市場:2016年∼2020年 Global Testosterone Replacement Therapy Market 2016-2020
出版日期: 2016年07月27日 內容資訊: 英文 59 Pages
簡介

睪酮(睪丸激素)替代療法 (TRT)又被稱作雄激素補充療法,主要用於治療性腺功能降低症。全球睪酮(睪丸激素)替代療法 (TRT) 市場在2016年∼2020年這段期間,預測將以年複合成長率(CAGR)3.35%的速度成長。

本報告提供全球睪酮(睪丸激素)替代療法 (TRT) 市場相關調查分析,提供您市場概要,各市場區隔考察,各地區考察,推動市場的要素,主要企業等概括性分析、彙整資料。

第1章 摘要整理

第2章 報告的範圍

第3章 市場調查的方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 性腺功能降低症

  • 所謂性腺功能降低症
  • 病理生理學
  • 症狀
  • 診斷
  • 治療

第6章 開發平台分析

第7章 主要購買標準

第8章 市場的狀況

  • 全球內分泌藥市場
  • 全球睪酮(睪丸激素)替代療法市場
  • 波特的五力分析

第9章 睪酮(睪丸激素)替代療法 (TRT)的全球市場:劑型

  • 凝膠
  • 注射
  • 貼片
  • 其他

第10章 睪酮(睪丸激素)替代療法 (TRT)的全球市場:各地區

  • 全球睪酮(睪丸激素)替代療法市場:各地區:2015年∼2020年
  • 南北美洲
  • 歐洲/中東/非洲
  • 亞太地區

第11章 睪酮(睪丸激素)替代療法 (TRT)的全球市場:促進要素

  • 老年人口的增加
  • 睪固酮缺乏症的增加
  • 慢性疾病的增加
  • 關注度提升

第12章 促進要素的影響

第13章 睪酮(睪丸激素)替代療法 (TRT)的全球市場:課題

第14章 促進要素與課題的影響

第15章 睪酮(睪丸激素)替代療法 (TRT)的全球市場:趨勢

  • SARMs的進入
  • 患者支援計劃
  • 重視新興市場
  • 在新治療指標的應用

第16章 供應商狀況

第17章 附錄

第18章 Technavio的其他的報告

目錄
Product Code: IRTNTR9274

About Testosterone Replacement Therapy

Testosterone replacement therapy, also called androgen replacement therapy, is typically used to treat hypogonadism. Testosterone, a hormone produced by the testes, is responsible for the development of secondary sexual characters in men. The levels of testosterone decrease gradually with age, but sometimes this decline is seen even in young men, leading to a condition known as hypogonadism. This can be treated with external supply of testosterone in the form of gels, patches, injectable, or oral drugs.

Technavio's analysts forecast the global testosterone replacement therapy market is gradually declining and will post a CAGR of (3.35) % during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global testosterone replacement therapy market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs that treat and prevent hypogonadism.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Testosterone Replacement Therapy Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Allergan
  • Eli Lilly and Company
  • Endo Pharmaceuticals

Other Prominent Vendors

  • Acerus Pharmaceuticals Corporation
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Bedford Labs
  • Clarus Therapeutics
  • Ferring Pharmaceuticals
  • Forendo Pharma
  • Juniper Pharmaceuticals
  • Lipocine
  • MetP Pharma
  • Mylan
  • Pfizer
  • ProStrakan Group
  • Repros Therapeutics
  • Sandoz
  • TesoRx
  • Teva Pharmaceuticals

Market driver

  • Increase in older population
  • For a full, detailed list, view our report

Market challenge

  • FDA warnings on use of testosterone products
  • For a full, detailed list, view our report

Market trend

  • Entry of SARMs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Hypogonadism

  • Understanding Hypergonadism
  • Pathophysiology
  • Symptoms
  • Diagnosis
  • Treatment

PART 06: Pipeline analysis

  • TESTAVAN
  • Vibex QST
  • LPCN 1021
  • REXTORO
  • Enclomiphene
  • LPCN 1111
  • TSX-002
  • TEFINA
  • THG-1001
  • MetP Testosterone Nasal Gel

PART 07: Key buying criteria

PART 08: Market landscape

  • Global endocrinology drugs market
  • Global testosterone replacement therapy market
  • Five forces analysis

PART 09: Market segmentation by dosage form

  • Gels
  • Injectables
  • Patches
  • Others

PART 10: Geographical segmentation

  • Global testosterone replacement therapy market by geography 2015-2020
  • Testosterone replacement therapy market in Americas
  • Testosterone replacement therapy market in EMEA
  • Testosterone replacement therapy market in APAC

PART 11: Market drivers

  • Increase in older population
  • High incidence of testosterone deficiency
  • Rise in chronic diseases
  • Increase in awareness

PART 12: Impact of drivers

PART 13: Market challenges

  • Generic erosion
  • FDA warnings on use of testosterone products
  • Adverse effects
  • Physicians are reluctant to prescribe medications with testosterone
  • Reluctance to discuss condition

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Entry of SARMs
  • Support of patient assistance programs
  • Focus on emerging markets
  • Application in new therapeutic indications

PART 16: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • AbbVie
  • Allergan
  • Eli Lilly
  • Endo International
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Normal levels of testosterone based on gender
  • Exhibit 03: Normal levels of testosterone at different ages
  • Exhibit 04: Timeline of testosterone replacement therapy products
  • Exhibit 05: Advantages and risks associated with use of testosterone products
  • Exhibit 06: Causes of hypogonadism
  • Exhibit 07: Symptoms of hypogonadism
  • Exhibit 08: Diagnostic algorithm of hypogonadism
  • Exhibit 09: Pipeline portfolio: Global testosterone drugs market
  • Exhibit 10: Key buying criteria for testosterone replacement therapy
  • Exhibit 11: Global endocrinology drugs market 2015-2020 ($ billions)
  • Exhibit 12: Market share of global testosterone replacement therapy market in global endocrinology drugs market
  • Exhibit 13: Global testosterone replacement therapy market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global testosterone replacement therapy market by dosage form 2015
  • Exhibit 16: Segmentation of global testosterone replacement therapy market based on geography 2015
  • Exhibit 17: Global testosterone replacement therapy market by geography 2015-2020 ($ billions)
  • Exhibit 18: Global testosterone replacement therapy market by geography 2015-2020
  • Exhibit 19: Testosterone replacement therapy market in Americas 2015-2020 ($ billions)
  • Exhibit 20: Percentage share of US in testosterone replacement therapy market 2015
  • Exhibit 21: Testosterone replacement therapy market in EMEA 2015-2020 ($ billions)
  • Exhibit 22: Testosterone replacement therapy market in EMEA 2015-2020 ($ billions)
  • Exhibit 23: Global testosterone replacement therapy market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ billions)
  • Exhibit 27: AbbVie: Key takeaways
  • Exhibit 28: Allergan: Key takeaways
  • Exhibit 29: Eli Lilly: YoY revenue and growth rate of Axiron 2013-2015 ($ millions)
  • Exhibit 30: Geographical segmentation of Axiron by revenue 2015
  • Exhibit 31: Eli Lilly: Key takeaways
  • Exhibit 32: Endo International: YoY revenue and growth rate of Fortesta 2013-2015 ($ millions)
  • Exhibit 33: Endo: Key takeaways
Back to Top